These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
410 related articles for article (PubMed ID: 31326373)
1. The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new. Chanson P; Maiter D Best Pract Res Clin Endocrinol Metab; 2019 Apr; 33(2):101290. PubMed ID: 31326373 [TBL] [Abstract][Full Text] [Related]
4. Controversial issues in the management of hyperprolactinemia and prolactinomas - An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism. Vilar L; Abucham J; Albuquerque JL; Araujo LA; Azevedo MF; Boguszewski CL; Casulari LA; Cunha Neto MBC; Czepielewski MA; Duarte FHG; Faria MDS; Gadelha MR; Garmes HM; Glezer A; Gurgel MH; Jallad RS; Martins M; Miranda PAC; Montenegro RM; Musolino NRC; Naves LA; Ribeiro-Oliveira Júnior A; Silva CMS; Viecceli C; Bronstein MD Arch Endocrinol Metab; 2018; 62(2):236-263. PubMed ID: 29768629 [TBL] [Abstract][Full Text] [Related]
5. Hyperprolactinemia and prolactinoma. Romijn JA Handb Clin Neurol; 2014; 124():185-95. PubMed ID: 25248588 [TBL] [Abstract][Full Text] [Related]
6. Update on prolactinomas. Part 2: Treatment and management strategies. Wong A; Eloy JA; Couldwell WT; Liu JK J Clin Neurosci; 2015 Oct; 22(10):1568-74. PubMed ID: 26243714 [TBL] [Abstract][Full Text] [Related]
7. Hyperprolactinemia and prolactinomas. Mancini T; Casanueva FF; Giustina A Endocrinol Metab Clin North Am; 2008 Mar; 37(1):67-99, viii. PubMed ID: 18226731 [TBL] [Abstract][Full Text] [Related]
13. Hyperprolactinemia after menopause: Diagnosis and management. Auriemma RS; Pirchio R; Pivonello R; Colao A Maturitas; 2021 Sep; 151():36-40. PubMed ID: 34446277 [TBL] [Abstract][Full Text] [Related]
14. [Some issues in the diagnosis and treatment of hyperprolactinemia]. Jin ZM Zhonghua Fu Chan Ke Za Zhi; 2008 Apr; 43(4):241-3. PubMed ID: 18843959 [No Abstract] [Full Text] [Related]
15. T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists. Burlacu MC; Maiter D; Duprez T; Delgrange E Endocrine; 2019 Feb; 63(2):323-331. PubMed ID: 30267354 [TBL] [Abstract][Full Text] [Related]
16. [Current diagnosis and treatment of hyperprolactinemia]. Melgar V; Espinosa E; Sosa E; Rangel MJ; Cuenca D; Ramírez C; Mercado M Rev Med Inst Mex Seguro Soc; 2016; 54(1):111-21. PubMed ID: 26820213 [TBL] [Abstract][Full Text] [Related]
17. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Casanueva FF; Molitch ME; Schlechte JA; Abs R; Bonert V; Bronstein MD; Brue T; Cappabianca P; Colao A; Fahlbusch R; Fideleff H; Hadani M; Kelly P; Kleinberg D; Laws E; Marek J; Scanlon M; Sobrinho LG; Wass JA; Giustina A Clin Endocrinol (Oxf); 2006 Aug; 65(2):265-73. PubMed ID: 16886971 [TBL] [Abstract][Full Text] [Related]
18. Approach to the Patient With Prolactinoma. Auriemma RS; Pirchio R; Pivonello C; Garifalos F; Colao A; Pivonello R J Clin Endocrinol Metab; 2023 Aug; 108(9):2400-2423. PubMed ID: 36974474 [TBL] [Abstract][Full Text] [Related]
19. Clinical Characteristics and Outcomes of Prolactinomas in Children and Adolescents: A Large Retrospective Cohort Study. Yang Y; Ke X; Duan L; Yang H; Gong F; Pan H; Wang L; Zhu H J Clin Endocrinol Metab; 2024 Aug; 109(9):e1741-e1749. PubMed ID: 38164002 [TBL] [Abstract][Full Text] [Related]